Results 31 to 40 of about 1,571,779 (177)

p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia [PDF]

, 2011
Background: The t(9;22) translocation leads to the formation of the chimeric breakpoint cluster region/c-abl oncogene 1 (BCR/ABL) fusion gene on der22, the Philadelphia chromosome.
Mahajna, Jamal, Y. Najajreh, Ruthardt, Martin, M. Ruthardt, Ottmann, Oliver G., J. Mahajna, Mian, Afsar Ali, Mian, Afsar A., Metodieva, Anna, Najajreh, Yousef, A. Metodieva, A. A. Mian, O. G. Ottmann   +12 more
core   +1 more source

Clinical and molecular characterization of early T-cell precursor leukemia : a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations [PDF]

, 2012
A subgroup of pediatric acute T-lymphoblastic leukemia (T-ALL) was characterized by a gene expression profile comparable to that of early T-cell precursors (ETPs) with a highly unfavorable outcome.
Hoelzer, Dieter, Farhadi-Sartangi, Nasrin, Schlee, Cornelia, Hofmann, Wolf-Karsten, Thiel, Eckhard, Burmeister, Thomas, Neumann, Martin, Thibaut, Julia, Gökbuget, Nicola, Heesch, Sandra, Schwartz, Stefan, Benlasfer, Ouidad, Baldus, Claudia   +12 more
core   +1 more source

Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia - a randomised SAL pilot study [PDF]

, 2012
INTRODUCTION: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in patients with low proliferating AML.
Ulrich Dührsen, Anja Koschmieder (106749), Matthias Stelljes, Christian Thiede (106768), Carsten Müller-Tidow, Nicola Tidow (106758), Noppeney, Richard, Utz Krug, Gerhard Ehninger, Daniela Schwammbach (106754), Steffen Koschmieder, Nicola Tidow, Wolfgang E Berdel, Markus Schaich (106764), Stelljes, Matthias, Matthias Stelljes (106772), Utz Krug (106744), Carsten Müller-Tidow (105305), Krug, Utz, Tidow, Nicola, Bug, Gesine, Schaich, Markus, Björn Steffen, Richard Noppeney (106769), Gerss, Joachim, Christian Thiede, Joachim Gerss, Schwammbach, Daniela, Thomas Büchner, Björn Steffen (106759), Büchner, Thomas, Ulrich Dührsen (106782), Anja Koschmieder, Christoph Röllig, Steffen, Björn, Markus Schaich, Steffen Koschmieder (106779), Thomas Büchner (106775), Hubert Serve, Koschmieder, Steffen, Christian H. Brandts (106762), Ehninger, Gerhard, Brandts, Christian Hubertus, Berdel, Wolfgang E., Joachim Gerss (106757), Gerhard Ehninger (106788), Dührsen, Ulrich, Wolfgang E. Berdel (106792), Richard Noppeney, Gesine Bug (106760), Serve, Hubert, Müller-Tidow, Carsten, Daniela Schwammbach, Christian H Brandts, Hubert Serve (106786), Thiede, Christian, Gesine Bug, Koschmieder, Anja, Röllig, Christoph, Christoph Röllig (106766), Koschmieder Steffen, Ehninger, G. (Gerhard), Schaich, M. (Markus), Tidow Nicola, Gerß, J. (Joachim), Müller-Tidow, C. (Carsten), Steffen Björn, Röllig, C. (Christoph), Thiede Christian, Dührsen, U. (Ulrich), Bug Gesine, Brandts, C.H. (Christian), Stelljes Matthias, Thiede, C. (Christian), Brandts Christian H., Noppeney, R. (Richard), Büchner, T. (Thomas), Schaich Markus, Tidow, N. (Nicola), Schwammbach, D. (Daniela), Röllig Christoph, Steffen, B. (Björn), Koschmieder Anja, Serve, H. (Hubert), Koschmieder, A. (Anja), Noppeney Richard, Bug, G. (Gesine), Krug Utz, Dührsen Ulrich, Stelljes, M. (Matthias), Berdel, W.E. (Wolfgang), Büchner Thomas, Schwammbach Daniela, Serve Hubert, Krug, U. (Utz), Berdel Wolfgang E., Ehninger Gerhard, Koschmieder, S. (Steffen), Gerss Joachim, Müller-Tidow Carsten   +99 more
core   +2 more sources

A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Ibrutinib has demonstrated inhibition of ErbB/HER tyrosine kinases in preclinical models. This Phase I/II study investigated the safety, efficacy, and immunomodulatory effects of ibrutinib in combination with trastuzumab in patients with HER2‐positive metastatic breast cancer (MBC) whose disease had progressed on ado‐trastuzumab emtansine ...
Joyce O'Shaughnessy, Andrea Glidden, Tracy Locke, Amy Scales, Elizabeth Gatewood, Jean‐Philippe Blanck, Jessica Castaneda‐Gill, Sharlin Patel, Yolanda D. Mahnke, Xuan Wang, Page Blas   +10 more
wiley   +1 more source

FLT3 mutations in Early T-Cell Precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors [PDF]

, 2013
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) has been identified as high-risk subgroup of acute T-lymphoblastic leukemia (T-ALL) with a high rate of FLT3-mutations in adults.
Hartmut Döhner (276603), Hofmann, Wolf-Karsten, Christian Brandts, Ulrich Dührsen, Eckhard Thiel (66496), Mochmann, Liliana H., Burmeister, Thomas, Lars Fransecky, Neumann, Martin, Döhner, Hartmut, Eckhard Thiel, Nicola Gökbuget, Claudia D Baldus, Martin Griesshammer (276602), Rainer Haas (81562), Sartangi, Nasrin Farhadi, Martin Neumann (276593), Gerhard Ehninger, Schwartz, Stefan, Dieter Hoelzer, Stefan Schwartz (276600), Nicola Gökbuget (276599), Olga Blau, Isabelle Bartram, Bartram, Isabelle, Thiel, Eckhard, Liliana H Mochmann, Wolf-Karsten Hofmann, Thomas Burmeister, Martin Neumann, Martin Griesshammer, Sandra Heesch (276598), Heesch, Sandra, Haas, Rainer, Rainer Haas, Schlee, Cornelia, Fransecky, Lars, Ulrich Dührsen (106782), Griesshammer, Martin, Christian Brandts (276601), Lars Fransecky (276595), Ebru Coskun, Claudia D. Baldus (66494), Isabelle Bartram (276596), Wolf-Karsten Hofmann (66497), Ehninger, Gerhard, Brandts, Christian Hubertus, Baldus, Claudia, Gerhard Ehninger (106788), Dührsen, Ulrich, Hoelzer, Dieter, Cornelia Schlee, Dieter Hoelzer (551), Cornelia Schlee (105296), Ebru Coskun (276594), Gökbuget, Nicola, Sandra Heesch, Liliana H. Mochmann (105294), Hartmut Döhner, Nasrin Farhadi Sartangi, Nasrin Farhadi Sartangi (276597), Thomas Burmeister (276604), Stefan Schwartz, Coskun, Ebru, Olga Blau (276605), Blau, Olga   +65 more
core   +2 more sources

Coronary Microvascular Dysfunction: Epidemiology, Pathophysiology, Diagnosis, and Treatment

MedComm, Volume 7, Issue 8, August 2026.
This visual summary illustrates the key aspects of coronary microvascular dysfunction (CMD) in angina with nonobstructive coronary artery disease (NOCAD), including epidemiology, pathophysiology (microvascular remodeling and endothelial dysfunction), the protective NRG‐1/ErbB signaling pathway, diagnostic methods, and both Western and traditional ...
Zhao Ge, MaoZe Zhang, Xujin Ning, Yijia Du, Lishuo Su, Xudong Wu, Jingyi Zhang, Tongzuo Liu, Xianliang Wang   +8 more
wiley   +1 more source

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML 10 and 12 trials [PDF]

, 2005
Fetal liver tyrosine kinase 3 (FLT3) internal tandem duplications (ITDs) are powerful adverse prognostic indicators for relapse in acute myelold leukemia (AML) but the most efficacious therapy for FLT3/ ITD+ patients is currently unknown.
Wheatley, Keith, Burnett, Alan Kenneth, Gale, RE, Hills, Robert Kerrin, Kottaridis, Panagiotis D., Linch, David C., Burnett, AK, Kottaridis, PD, Srirangan, S, Hills, Robert, Hills, R, Srirangan, Sivatharsini, Wheatley, K, Gale, Rosemary E., Linch, DC   +14 more
core   +1 more source

Post‐translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases

MedComm, Volume 7, Issue 4, April 2026.
Posttranslational modifications (PTMs) serve as rapid and reversible molecular switches that reshape protein activity, stability, and interactomes, thereby governing virtually all physiological cues ranging from signal transduction to epigenetic memory. Mass spectrometry‐based proteomics has substantially expanded our understanding of PTM emergence and
Shuning Zhang, Jingmin Li, Meihuan Chen, Hailong Huang   +3 more
wiley   +1 more source

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993 [PDF]

, 2005
The international acute lymphoblastic leukemia (ALL) study was designed to prospectively define the optimal therapy for adults 60 years of age or younger with newly diagnosed ALL.
Burnett, Alan Kenneth, Franklin, IM, Rowe, Jacob M., Richards, SM, Litzow, Mark R., Wiernik, P.H., Tallman, Martin S., Rowe, JM, Prentice, H. Grant, Goldstone, Anthony H., Wiernik, PH, Litzow, M.R., Litzow, MR, Ciobanu, N, Ciobanu, N., Prentice, HG, Durrant, J., Richards, Susan M., Durrant, J, Lazarus, H.M., Goldstone, A.H., Chopra, R, Lazarus, Hillard M., Wiernik, Peter H., Ciobanu, Niculae, Rowe, J.M., Tallman, MS, Durrant, Jill, Chopra, R., Lazarus, HM, Burnett, AK, Burnett, A.K., Buck, Georgina, Buck, G., Franklin, Ian M., Chopra, Raj, Goldstone, AH, Prentice, H.G., Richards, S.M., Tallman, M.S., Buck, G, Franklin, I.M.   +41 more
core   +1 more source

Pure Erythroleukemia (Variant Acute Myeloid Leukemia-vAML-M6) with Deletion of Chromosome 20, Mainly Presenting as Late Erythroblasts, a Unique Case Report with Review of Literature [PDF]

Indian Journal of Hematology and Blood Transfusion, 2012
Acute erythroleukemia is characterized by a predominant immature erythroid population and accounts for approximately 2-5 % of all cases of acute leukemia. Two subtypes are recognized based on the presence or absence of a significant myeloid component: erythroleukemia and pure erythroid leukemia.
Javid, Rasool, Sajad, Geelani, , Khursheed, , Yasir, Mohd Suhail, Lone, Mohd, Shaban   +5 more
openaire   +2 more sources